Month: August 2020

Geneva, Switzerland, August 31, 2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that that Tim Dyer, Chief Executive Officer, is scheduled to participate at the Biotechgate Digital Partnering Conference taking place on August 31 – September 3, 2020.Mr. Dyer and Dr. Lütjens will be available for one-on-one meetings during the conference. Meetings can be requested via the Partnering Biotech Webpage for those who registered to participate.About Addex TherapeuticsAddex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several...

Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United StatesIdorsia and Syneos Health collaborate to lead the transformation and modernization of the insomnia market in the USSyneos Health selected for their robust customer-facing sales expertise to effectively reach the primary care marketAllschwil, Switzerland and Morrisville, N.C.– August 31, 2020Idorsia Ltd (SIX: IDIA) and Syneos Health (Nasdaq: SYNH) today announced an innovative commercial relationship for the US commercialization of Idorsia’s daridorexant, a new dual orexin receptor antagonist being investigated for the treatment of insomnia. The strategic collaboration brings Idorsia’s lead investigational compound, daridorexant, and expertise in the science of the orexin system, together with Syneos Health’s robust customer-facing sales...

Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United StatesIdorsia and Syneos Health collaborate to lead the transformation and modernization of the insomnia market in the USSyneos Health selected for their robust customer-facing sales expertise to effectively reach the primary care marketAllschwil, Switzerland and Morrisville, N.C.– August 31, 2020Idorsia Ltd (SIX: IDIA) and Syneos Health (Nasdaq: SYNH) today announced an innovative commercial relationship for the US commercialization of Idorsia’s daridorexant, a new dual orexin receptor antagonist being investigated for the treatment of insomnia. The strategic collaboration brings Idorsia’s lead investigational compound, daridorexant, and expertise in the science of the orexin system, together with Syneos Health’s robust customer-facing sales...

Un comité de surveillance de l’innocuité (CSI) indépendant préprogrammé a recommandé que l’étude de phase 2 sur le COVID-19 aux États-Unis avec l’opaganib se poursuive sans changement ; le recrutement pour l’étude est complété à plus de 50 % et il devrait être terminé au cours des prochaines semaines—L’étude mondiale de phase 2/3 sur le COVID-19 avec l’opaganib, qui se déroule en parallèle de l’étude de phase 2 aux États-Unis, a été approuvée en Italie ; cette étude a aussi été approuvée au Royaume-Uni, en Russie et au Mexique, et est en cours d’examen dans d’autres pays—Les premiers patients ont été inscrits dans l’étude mondiale de phase 2/3 avec l’opaganib, qui devrait recruter jusqu’à 270 patients hospitalisés atteints d’une pneumonie sévère...

Nach einer vorab geplanten Überprüfung hat ein unabhängiges Sicherheitsüberwachungskomitee empfohlen, die US-amerikanische COVID-19-Studie der Phase II zu Opaganib unverändert fortzusetzen. Mehr als 50 % der geplanten Patienten sind aufgenommen und die Rekrutierung soll in den kommenden Wochen abgeschlossen sein—Die globale COVID-19-Studie der Phase II/III zu Opaganib, die parallel zur US-amerikanischen Phase-II-Studie durchgeführt wurde, wurde in Italien genehmigt. Diese Studie wurde auch in Großbritannien, Russland und Mexiko genehmigt und wird in weiteren Ländern geprüft—Die ersten Patienten wurden in die globale Phase-II/III-Studie zu Opaganib aufgenommen, an der bis zu 270 Patienten mit schwerer COVID-19-Pneumonie an bis zu 40 klinischen Prüfzentren teilnehmen sollen—Mögliche Einreichung globaler Anträge auf Notfallnutzung...

Un Comitato indipendente di monitoraggio della sicurezza (SMC) preprogrammato ha rilasciato una raccomandazione affinché lo studio USA COVID-19 di fase 2 su opaganib continui senza variazioni; la fase di arruolamento, in copertura già per oltre il 50%, verrà completata nelle prossime settimane—Lo studio globale COVID-19 di fase 2/3 su opaganib, condotto parallelamente allo studio USA di fase 2, è stato approvato in Italia; lo stesso studio ha ottenuto l’approvazione anche nel Regno Unito, Russia e Messico ed è in fase di revisione in altri paesi—I primi pazienti sono stati arruolati nello studio globale di fase 2/3 su opaganib, destinato ad arruolare fino a 270 pazienti ricoverati con polmonite grave da COVID-19 in un massimo di 40 siti clinici—Potenziale richiesta globale di applicazioni per uso d’emergenza già nel...

Company announcement 9/2020 (31 August 2020)European Energy delivers a solid start for the first half year for the Group and maintains its high expectations for the annual targets. The second quarter had revenue of EUR 37.2 million, an EBITDA of EUR 9.4 million and profit before tax of EUR 3.7 million. This concludes the first half of 2020 with a strong revenue of 65.9 million, an EBITDA of EUR 19.7 million and profit before tax of EUR 7.9 million.Knud Erik Andersen, CEO of European Energy, says:“We are pleased to report that European Energy delivers healthy and profitable growth in the first half of 2020, as we maintain our expectations for our annual targets.The increased sale of green power was the main driver behind the profitable growth. Electricity sales are up by 120% in the second quarter of 2020 compared to the same period in...

Trading Update and Financial GuidanceLondon, Aug. 30, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Rapid Nutrition PLC (SW:RAP, OTCQB:RPNRF), a natural wellness company focused on organic wholefood-based nutrition and science-based herbal products, announced the following trading update ahead of the publication of its Interim Results for the period ended 30 June 2020, scheduled to be released on 30 September 2020.Even during a global pandemic, the company continues to realize strong market demand for health supplements, with its flagship brand SystemLS™ in particular, including a variety of organic and natural high-protein vegan shakes, superfoods, whey protein, metabolism boosters and high-fiber bars. 2020 Interim Financial HighlightsFinancial highlights for the period to date include:Revenue for the period reached $3.375 million,...

— Supplemental NDAs for Toripalimab filed— Expanding into infectious disease and collaborating with IMCAS and Lilly for COVID-19 neutralizing antibodies— Dual Listing on the STAR MarketSHANGHAI, China, Aug. 30, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced its financial results for the six months ended June 30, 2020 and provided corporate updates.First Half 2020 Financial HighlightsTotal revenues reached RMB575 million in the first half year of 2020, representing an 86% increase compared with the first half year of 2019. Sales of Toripalimab was RMB426 million, out of which RMB254 million was generated in the second quarter, representing recovery...

一个预先安排的独立安全监测委员会（SMC）建议使用opaganib治疗新冠肺炎的美国2期研究按原方案进行；该项研究的患者招募已完成超过50%，预计招募工作将在未来数周完成—与美国2期研究同时进行的opaganib治疗新冠肺炎全球2/3期研究在意大利获得批准；这项研究已经在英国、俄罗斯和墨西哥获得批准，并正在其他一些国家接受审核—opaganib全球2/3期研究已完成首批患者招募，总共计划在40处临床研究中心招募270名重症新冠肺炎住院患者—最早可能于2020年第四季度提交全球紧急用药申请